{"sha1":"23497384029aef37285da204f78124637251893a","filename":"pembrolizumab-summary-of-advice.pdf","mimetype":"application/pdf","filesize_bytes":42403,"metadata":{"info":{"/SourceModified":"D:20151130201701","/Objective-IsPublished":"1","/Objective-Classification":"[Inherited - none]","/Objective-VersionComment":"","/Objective-Owner":"Simon England","/Objective-DOCSOpen#20Security#20#5bsystem#5d":"","/Objective-DOCSOpen#20Document#20Type#20#5bsystem#5d":"","/Objective-Parent":"Pembrolizumab","/Objective-Caveats":"","/Keywords":"","/Objective-ModificationStamp":"D:20151201","/Objective-Connect#20Creator#20#5bsystem#5d":"","/Objective-CreationStamp":"D:20151112","/Company":"Pharmac","/Author":"Lisa Williams","/Producer":"Adobe PDF Library 10.0","/Objective-Comment":"","/Objective-State":"Published","/Objective-VersionNumber":"27.000000","/Title":" ","/Objective-Id":"A841418","/Objective-DOCSOpen#20Document#20Number#20#5bsystem#5d":"","/Subject":"","/Objective-FileNumber":"qA36433","/Objective-Inherit#20Keyword#20#5bsystem#5d":"Y","/Creator":"Acrobat PDFMaker 10.0 for Word","/ModDate":"D:20151201103318+13'00'","/Objective-DOCSOpen#20System#20ID#20#5bsystem#5d":"","/Objective-IsApproved":"0","/Objective-DatePublished":"D:20151201","/Objective-Title":"2015-12-02 Clinical review of pembrolizumab (Keytruda) - summary of advice","/Objective-DOCSOpen#20Document#20Author#20#5bsystem#5d":"","/Objective-Version":"2.0","/CreationDate":"D:20151201103317+13'00'","/Objective-Path":"Objective Global Folder:PHARMAC Fileplan:External relations:Strategy and Planning:Communications planning and strategy 2015/16:Communications Activity 2015/16:Pembrolizumab:"},"xmp":{"stream":"{'/Type': '/Metadata', '/Subtype': '/XML'}","__doc__":"\n    An object that represents Adobe XMP metadata.\n    Usually accessed by :meth:`getXmpMetadata()<PyPDF2.PdfFileReader.getXmpMetadata>`\n    ","pdf_producer":"Adobe PDF Library 10.0","dc_identifier":"None","xmpmm_documentId":"uuid:2e62f025-9667-4176-9e76-823468df90e2","dc_subject":[],"dc_description":"{'x-default': ''}","xmp_creatorTool":"Acrobat PDFMaker 10.0 for Word","xmp_createDate":"2016-07-04 21:13:56.491695","dc_title":"{'x-default': ' '}","dc_language":[],"xmpmm_instanceId":"uuid:c220eda1-747d-48d4-82d1-bbc90b501dc2","dc_rights":{},"__dict__":"{'stream': {'/Type': '/Metadata', '/Subtype': '/XML'}, 'rdfRoot': <DOM Element: rdf:RDF at 0x7faa4b500f20>, 'cache': {}}","dc_publisher":[],"dc_coverage":"None","dc_date":[],"__weakref__":"None","pdf_keywords":"","xmp_modifyDate":"2016-07-04 21:13:56.491934","custom_properties":"{'Objective-Parent': 'Pembrolizumab', 'Objective-ModificationStamp': 'D:20151201', 'Objective-VersionComment': '', 'Objective-DOCSOpen Document Author [system]': '', 'Objective-Comment': '', 'Objective-Version': '2.0', 'Objective-DOCSOpen Document Number [system]': '', 'Objective-Path': 'Objective Global Folder:PHARMAC Fileplan:External relations:Strategy and Planning:Communications planning and strategy 2015/16:Communications Activity 2015/16:Pembrolizumab:', 'Objective-Owner': 'Simon England', 'Objective-DatePublished': 'D:20151201', 'Objective-Title': '2015-12-02 Clinical review of pembrolizumab (Keytruda) - summary of advice', 'Objective-DOCSOpen System ID [system]': '', 'Objective-IsPublished': '1', 'Objective-Id': 'A841418', 'Objective-DOCSOpen Document Type [system]': '', 'Objective-Connect Creator [system]': '', 'SourceModified': 'D:20151130201701', 'Objective-Caveats': '', 'Objective-IsApproved': '0', 'Objective-State': 'Published', 'Objective-VersionNumber': '27.000000', 'Objective-CreationStamp': 'D:20151112', 'Objective-Inherit Keyword [system]': 'Y', 'Objective-Classification': '[Inherited - none]', 'Objective-FileNumber': 'qA36433', 'Objective-DOCSOpen Security [system]': '', 'Company': 'Pharmac'}","pdf_pdfversion":"None","cache":{},"dc_format":"application/pdf","rdfRoot":{"rdf:RDF":{"@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","rdf:Description":[{"@rdf:about":"","@xmlns:xmp":"http://ns.adobe.com/xap/1.0/","xmp:ModifyDate":"2015-12-01T10:33:18+13:00","xmp:CreateDate":"2015-12-01T10:33:17+13:00","xmp:MetadataDate":"2015-12-01T10:33:18+13:00","xmp:CreatorTool":"Acrobat PDFMaker 10.0 for Word"},{"@rdf:about":"","@xmlns:xmpMM":"http://ns.adobe.com/xap/1.0/mm/","xmpMM:DocumentID":"uuid:2e62f025-9667-4176-9e76-823468df90e2","xmpMM:InstanceID":"uuid:c220eda1-747d-48d4-82d1-bbc90b501dc2","xmpMM:subject":{"rdf:Seq":{"rdf:li":"36"}}},{"@rdf:about":"","@xmlns:dc":"http://purl.org/dc/elements/1.1/","dc:format":"application/pdf","dc:title":{"rdf:Alt":{"rdf:li":{"@xml:lang":"x-default"}}},"dc:description":{"rdf:Alt":{"rdf:li":{"@xml:lang":"x-default"}}},"dc:creator":{"rdf:Seq":{"rdf:li":"Lisa Williams"}}},{"@rdf:about":"","@xmlns:pdf":"http://ns.adobe.com/pdf/1.3/","pdf:Producer":"Adobe PDF Library 10.0","pdf:Keywords":null},{"@rdf:about":"","@xmlns:pdfx":"http://ns.adobe.com/pdfx/1.3/","pdfx:SourceModified":"D:20151130201701","pdfx:Company":"Pharmac","pdfx:Objective-Id":"A841418","pdfx:Objective-Comment":null,"pdfx:Objective-CreationStamp":"D:20151112","pdfx:Objective-IsApproved":"0","pdfx:Objective-IsPublished":"1","pdfx:Objective-DatePublished":"D:20151201","pdfx:Objective-ModificationStamp":"D:20151201","pdfx:Objective-Owner":"Simon England","pdfx:Objective-Path":"Objective Global Folder:PHARMAC Fileplan:External relations:Strategy and Planning:Communications planning and strategy 2015/16:Communications Activity 2015/16:Pembrolizumab:","pdfx:Objective-Parent":"Pembrolizumab","pdfx:Objective-State":"Published","pdfx:Objective-Title":"2015-12-02 Clinical review of pembrolizumab (Keytruda) - summary of advice","pdfx:Objective-Version":"2.0","pdfx:Objective-VersionComment":null,"pdfx:Objective-VersionNumber":"27.000000","pdfx:Objective-FileNumber":"qA36433","pdfx:Objective-Classification":"[Inherited - none]","pdfx:Objective-Caveats":null,"pdfx:Objective-DOCSOpenↂ0020Documentↂ0020Authorↂ0020ↂ005Bsystemↂ005D":null,"pdfx:Objective-DOCSOpenↂ0020Documentↂ0020Numberↂ0020ↂ005Bsystemↂ005D":null,"pdfx:Objective-DOCSOpenↂ0020Documentↂ0020Typeↂ0020ↂ005Bsystemↂ005D":null,"pdfx:Objective-DOCSOpenↂ0020Securityↂ0020ↂ005Bsystemↂ005D":null,"pdfx:Objective-DOCSOpenↂ0020Systemↂ0020IDↂ0020ↂ005Bsystemↂ005D":null,"pdfx:Objective-Inheritↂ0020Keywordↂ0020ↂ005Bsystemↂ005D":"Y","pdfx:Objective-Connectↂ0020Creatorↂ0020ↂ005Bsystemↂ005D":null}]}},"dc_creator":"['Lisa Williams']","dc_source":"None","dc_relation":[],"__module__":"PyPDF2.xmp","xmp_metadataDate":"2016-07-04 21:13:56.491856","dc_contributor":[],"dc_type":[]}},"url":"whaleoil.co.nz@@https://www.pharmac.govt.nz/assets/pembrolizumab-summary-of-advice.pdf"}